| Authors: |
Levillain H; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium. hugo.levillain@hubruxelles.be., Moës AR; IBA SA, RadioPharmaSolutions, Brussels, Belgium., Gameiro-Paris C; IBA SA, RadioPharmaSolutions, Brussels, Belgium., Abrunhosa A; Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal., Deakin T; LabLogic Systems Limited, Sheffield, UK., Gebhart G; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium., Herth MM; TetraKit Technologies ApS, University of Copenhagen, Copenhagen, Denmark.; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark., Gestin JF; Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, France., Haddad F; GIP Arronax, Saint-Herblain, and Subatech, Nantes, France., Jensen AI; TetraKit Technologies ApS, University of Copenhagen, Copenhagen, Denmark., Bue RL; The Oncidium Foundation, Brussels, Belgium., Mikolajczak R; Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland., Otamendi A; Vicomtech, San Sebastian, Spain., Staunton-Mann K; LabLogic Systems Limited, Sheffield, UK., Tabury K; Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium., Flamen P; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium. |
